XML 175 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Equity (Tables)
3 Months Ended
Mar. 31, 2023
Stockholders' Equity Note [Abstract]  
Schedule of Share-Based Compensation Expense The following table summarizes the components of our share-based compensation expense for the periods presented:
Three Months Ended March 31,
(in millions)20232022
Stock options:
Pre-tax compensation expense$$
Income tax benefit— — 
Stock option expense, net of income taxes
Restricted stock units ("RSUs"):
Pre-tax compensation expense
Income tax benefit(1)— 
RSUs, net of income taxes
Performance shares and other share-based awards:
Pre-tax compensation expense
Income tax benefit— (1)
Performance shares and other share-based compensation expense, net of income taxes
Total share-based compensation:
Pre-tax compensation expense
Income tax benefit(1)(1)
Total share-based compensation expense, net of income taxes$$
Schedule of Valuation Assumptions for Stock Options The fair value of each option grant was estimated using the Black-Scholes option-pricing model with the following assumptions:
Three Months Ended March 31,
20232022
Expected life (in years)5.55.5
Risk-free interest rate4.0 %2.0 %
Expected volatility28.3 %23.8 %
Expected dividend yield2.9 %2.9 %
Schedule of Stock Option Transactions
A summary of stock option transactions for the first quarter of 2023 is as follows:
Number of Options
(in thousands)
Weighted Average Exercise Price per ShareAverage Remaining Contractual Term (Years)Aggregate Intrinsic Value
(in millions)
Outstanding as of December 31, 20222,222$92.32 5.16$24 
Granted19798.69 
Exercised(148)63.51 
Cancelled— 
Outstanding as of March 31, 20232,271$94.75 5.61$25 
Exercisable as of March 31, 20231,786$95.38 4.67$20 
Schedule of Additional Information Pertaining to Stock Option Activity
Additional information pertaining to stock option activity is as follows:
Three Months Ended March 31,
(dollars in millions, except per share)20232022
Weighted average grant date fair value of stock options granted (per share)$23.80 $15.04 
Total intrinsic value of stock options exercised
Schedule of Restricted Unit Activity
The following table summarizes RSU activity during the first quarter of 2023:
(shares in thousands)Number of
Restricted
Shares
Weighted
Average
Fair Value
per Share
Non-vested at December 31, 2022517$88.04 
Granted20398.46 
Vested(137)88.44 
Cancelled(5)89.11 
Non-vested at March 31, 2023578$91.64 
Summary of Accumulated Other Comprehensive Loss The following is a summary of accumulated other comprehensive income (loss) for the first quarter of 2023 and 2022:
(in millions)Cumulative Translation AdjustmentHedging ActivitiesPension and Postretirement AdjustmentAOCL
Balance, December 31, 2022$(1,008)$$(46)$(1,048)
Other comprehensive income (loss) before reclassification adjustments (58)— (52)
(Gain) loss reclassified from accumulated OCL— (18)— (18)
Tax benefit— 20 — 20 
Net other comprehensive income (loss)(56)— (50)
Balance, March 31, 2023$(1,002)$(50)$(46)$(1,098)
(in millions)Cumulative Translation AdjustmentHedging ActivitiesPension and Postretirement AdjustmentAOCL
Balance, December 31, 2021$(903)$48 $(42)$(897)
Other comprehensive gain before reclassification adjustments38 176 — 214 
(Gain) reclassified from accumulated OCL— (46)— (46)
Tax (provision)— (34)— (34)
Net other comprehensive income38 96 — 134 
Balance, March 31, 2022$(865)$144 $(42)$(763)
Schedule of Basic and Diluted Earnings Per Common Share The following table provides the computation of basic and diluted earnings per common share (“EPS”) for the periods presented.
Three Months Ended March 31, 2023Three Months Ended March 31, 2022
(in millions, except per share amounts)Net Income
Available
to Ingredion
Weighted
Average
Shares
Per
Share
Amount
Net Income
Available
to Ingredion
Weighted
Average
Shares
Per
Share
Amount
Basic EPS$191 66.1$2.89 $130 66.9$1.94 
Effect of Dilutive Securities:
Incremental shares from assumed exercise of dilutive stock options and vesting of dilutive RSUs and other awards1.00.7
Diluted EPS$191 67.1$2.85 $130 67.6$1.92